Blueprint gears up for Ayvakit expansion, with blockbuster sales on the line

Stomach cancer may be a bust for Blueprint Medicines’ Ayvakit, but now the kinase inhibitor is nearing a potential FDA label expansion in a rare blood disorder. The company hopes this use can catapult the drug into blockbusterland.